Core Viewpoint - The approval of PB-119 by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its market position and potential revenue streams [1] Company Developments - The company's stock price increased by 5.11%, reaching HKD 63.8, with a trading volume of HKD 29.2559 million [1] - PB-119 is a new generation long-acting GLP-1 receptor agonist, administered once a week, and recognized as a Class 1 new drug by the national major science and technology project [1] - The company has established a strategic partnership with PDC FZ-LLC, granting exclusive rights for the development, distribution, marketing, and commercialization of PB-119 in the Middle East and Africa [1] Industry Impact - The approval of PB-119 is expected to contribute to the advancement of innovative drug development within the biopharmaceutical industry in China [1] - The collaboration with PDC represents a critical step in the company's global commercialization strategy, potentially expanding its market reach [1]
港股异动 | 派格生物医药-B(02565)涨超5% PB-119上市申请获批 公司加快全球商业化战略